Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $1.5 million.

  • Harvard Bioscience's Other Non-Current Liabilities fell 253.16% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 253.16%. This contributed to the annual value of $1.3 million for FY2024, which is 1497.29% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Other Non-Current Liabilities is $1.5 million, which was down 253.16% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Other Non-Current Liabilities registered a high of $2.8 million during Q1 2021, and its lowest value of $418000.0 during Q2 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $1.4 million (2025), whereas its average is $1.4 million.
  • In the last 5 years, Harvard Bioscience's Other Non-Current Liabilities skyrocketed by 23039.44% in 2021 and then tumbled by 8353.03% in 2022.
  • Over the past 5 years, Harvard Bioscience's Other Non-Current Liabilities (Quarter) stood at $486000.0 in 2021, then soared by 107.0% to $1.0 million in 2022, then skyrocketed by 46.72% to $1.5 million in 2023, then dropped by 14.97% to $1.3 million in 2024, then increased by 16.57% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.4 million for Q2 2025, and $1.4 million during Q1 2025.